Real-World Outcomes of Abemaciclib Versus Non-CDK4/6 Inhibitor Systemic Therapy in Dedifferentiated Liposarcoma: A Multicenter Propensity Score–Matched Analysis (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1125P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Real-world • Real-world evidence • Liposarcoma • Oncology • Sarcoma • Solid Tumor
|
|
Muhammad Nabeel Saddique; Maryam Abid; Muhammad A. Khokhar; Mehwish Manzoor; Qasim Mehmood; Eesha Farhan
|